Citations 2
Efficacy and Safety Results of INFRONT-3: A Phase 3 Randomized, Double-Blind, Placebo Controlled Study Evaluating Latozinemab (AL001) in FTD-GRN (LS2.002)
MAYORGA, ARTHUR, Boeve, Bradley, Ber, Isabelle Le, Mummery, Catherine, Rohrer, Jonathan, Onur, Oezguer, Boxer, Adam, Schwabe, Tina, Kahn, Olga, Huang, Julie, Gupta, Ruchi , Zhong, Jinglin , Carter, Lawrence, Nguyen, Tuan, Simmons, Adam, Chow, Tiffany, Budda, Balasubrahmanyam, Park, Lovingly, Jackson, Sam, Paul, Robert , Romano, Gary, Kenkare-Mitra, Sara, Rosenthal, Arnon , Salvadore, Giacomo , Mayorga, Arthur J., Ber, Isabelle Le , Borroni, Barbara , Mummery, Catherine J. , Zamboni, Giovanna , Onur, Oezguer A. , Rowe, James B , Boxer, Adam, Gupta, Ruchi, Li, Caiyan , Guizzetti, Leonardo , Carter, Lawrence , Simmons, Adam, Jackson, Sam, Romano, Gary, Kenkare-Mitra, Sara
Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available
Baseline Characteristics for INFRONT-3: A Phase 3 Double-Blind, Placebo-Controlled 96-Week Study Evaluating Latozinemab in FTD-GRN (P8-3.005)
Carter, Lawrence , Mummery, Catherine J. , Ber, Isabelle Le, Boeve, Bradley, Boxer, Adam L. , Chow, Tiffany W. , Huang, Julie , Salvadore, Giacomo , Romano, Gary, Borroni, Barbara , Ber, Isabelle Le , Smithey, Megan J. , Guizzetti, Leonardo
Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available